

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	5693322
<b>Application Number:</b>	10699517
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	8113
<b>Title of Invention:</b>	Prevention and treatment of synucleinopathic disease
<b>First Named Inventor/Applicant Name:</b>	Dale B. Schenk
<b>Customer Number:</b>	20350
<b>Filer:</b>	Rosemarie L. Celli/Tina Trieu
<b>Filer Authorized By:</b>	Rosemarie L. Celli
<b>Attorney Docket Number:</b>	015270-008920US
<b>Receipt Date:</b>	13-JUL-2009
<b>Filing Date:</b>	31-OCT-2003
<b>Time Stamp:</b>	20:01:22
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$180
RAM confirmation Number	6210
Deposit Account	201430
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

## File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		015270-008920_SID5_07-13-2009.pdf	295792 3c1f868ca24b3c6d607abcaae1f2a09d5a02088a6a	yes	5
<b>Multipart Description/PDF files in .zip description</b>					
	<b>Document Description</b>		<b>Start</b>		<b>End</b>
	Transmittal Letter		1		3
	Information Disclosure Statement (IDS) Filed (SB/08)		4		5
<b>Warnings:</b>					
<b>Information:</b>					
2	NPL Documents	240-AlvesDaCosta_.pdf	677046 f13739fe9a641b2afccaa28bb1b8fe059	no	8
<b>Warnings:</b>					
<b>Information:</b>					
3	NPL Documents	241-Casadesus_TheEstrogenMyth_2006.pdf	513347 541bb6e47c5c09f533bdc952118bcb6d3049d53e	no	8
<b>Warnings:</b>					
<b>Information:</b>					
4	NPL Documents	242-JanewayTravers_IMMUNOBio_1997.pdf	918196 014dc71e094b6c75621bdc6d6940152e825f5240e	no	5
<b>Warnings:</b>					
<b>Information:</b>					
5	NPL Documents	255-PCTSearchfor08103472.pdf	121772 895328a6109b757d4804b5a74ef05e0759e242a	no	3
<b>Warnings:</b>					
<b>Information:</b>					
6	NPL Documents	243-Perrin_EpitopeMapping_Abstr act.pdf	444367 2b616d7d4d499b2675724b48c0f04523aa35c8	no	4
<b>Warnings:</b>					
<b>Information:</b>					

7	NPL Documents	244- Sidhu_DoesAlphaSynuclein_2004.pdf	1199334 3d4f8ed13e2ba63d8f1a72a799e5d7995d81465c	no	11
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	245- Spillantini_AlphaSynucleinInLewyBodies_1997.pdf	240936 d4d87e6ade48c1455c08bede74f5e0c8f1c1780	no	2
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	246- Takeda_AbnormalAccum_1998.pdf	428192 ca8f8d2120cc04b4b25c5f1c2c0f1-e68a7adfe	no	6
<b>Warnings:</b>					
<b>Information:</b>					
10	NPL Documents	247- Tofaris_PhysiologicalProperties.pdf	729672 f41cc0f8e23847e7eeca7184718130aab959629	no	8
<b>Warnings:</b>					
<b>Information:</b>					
11	Fee Worksheet (PTO-875)	fee-info.pdf	30132 d70abab9e2c314dece183e303249779950579094	no	2
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			5598786		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

#### New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

#### National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

#### New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.